Published in Proc Natl Acad Sci U S A on December 07, 2009
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med (2013) 2.63
Self-assembling peptide nanotubes with antiviral activity against hepatitis C virus. Chem Biol (2011) 1.41
Inhibitors of alphavirus entry and replication identified with a stable Chikungunya replicon cell line and virus-based assays. PLoS One (2011) 1.37
Curing a viral infection by targeting the host: the example of cyclophilin inhibitors. Antiviral Res (2013) 1.10
A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle. Proc Natl Acad Sci U S A (2010) 1.02
Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection. Viruses (2015) 0.91
Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes. Antimicrob Agents Chemother (2013) 0.90
Early Events in Chikungunya Virus Infection-From Virus CellBinding to Membrane Fusion. Viruses (2015) 0.89
Inhibition of enveloped virus infection of cultured cells by valproic acid. J Virol (2010) 0.88
Hepatitis C virus experimental model systems and antiviral drug research. Virol Sin (2010) 0.87
Novel cell-based hepatitis C virus infection assay for quantitative high-throughput screening of anti-hepatitis C virus compounds. Antimicrob Agents Chemother (2013) 0.86
Antiviral stilbene 1,2-diamines prevent initiation of hepatitis C virus RNA replication at the outset of infection. J Virol (2011) 0.86
How hepatitis C virus invades hepatocytes: the mystery of viral entry. World J Gastroenterol (2014) 0.85
Ebselen inhibits hepatitis C virus NS3 helicase binding to nucleic acid and prevents viral replication. ACS Chem Biol (2014) 0.83
High-throughput screening and rapid inhibitor triage using an infectious chimeric Hepatitis C virus. PLoS One (2012) 0.80
Cryptoporus volvatus extract inhibits porcine reproductive and respiratory syndrome virus (PRRSV) in vitro and in vivo. PLoS One (2013) 0.80
Antiviral drugs against hepatitis C virus. Genet Vaccines Ther (2011) 0.78
Sigma-1 receptor regulates early steps of viral RNA replication at the onset of hepatitis C virus infection. J Virol (2013) 0.78
Hepatitis C Virus Particle Assembly Involves Phosphorylation of NS5A by the c-Abl Tyrosine Kinase. J Biol Chem (2015) 0.78
Interplay among cellular polarization, lipoprotein metabolism and hepatitis C virus entry. World J Gastroenterol (2011) 0.78
Identification of a resveratrol tetramer as a potent inhibitor of hepatitis C virus helicase. Br J Pharmacol (2015) 0.78
Inhibition of West Nile Virus Multiplication in Cell Culture by Anti-Parkinsonian Drugs. Front Microbiol (2016) 0.76
Screening and identification of compounds with antiviral activity against hepatitis B virus using a safe compound library and novel real-time immune-absorbance PCR-based high throughput system. Antiviral Res (2013) 0.76
The Polymerase Chain Reaction: Essential for the Development of Curative Therapy for Hepatitis C. Dig Dis Sci (2015) 0.75
Clinically approved ion channel inhibitors close gates for hepatitis C virus -and open doors for drug repurposing in viral infectious diseases. J Virol (2016) 0.75
Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay. Antiviral Res (2015) 0.75
Update on the Development of Anti-Viral Agents Against Hepatitis C. J Clin Transl Hepatol (2013) 0.75
Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine. Antimicrob Agents Chemother (2014) 0.75
Last stop before exit - hepatitis C assembly and release as antiviral drug targets. Viruses (2010) 0.75
Co-expression of VpROMT gene from Chinese wild Vitis pseudoreticulata with VpSTS in tobacco plants and its effects on the accumulation of pterostilbene. Protoplasma (2011) 0.75
Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science (1999) 24.31
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Efficient initiation of HCV RNA replication in cell culture. Science (2000) 15.12
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med (2003) 10.20
Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol (2005) 9.00
Replication of hepatitis C virus. Nat Rev Microbiol (2007) 8.31
Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature (2007) 7.04
Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A (2006) 6.87
Course and outcome of hepatitis C. Hepatology (2002) 6.51
Replication of hepatitis C virus. J Gen Virol (2000) 6.08
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. J Cell Biol (1993) 5.62
Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med (2000) 5.27
The vacuolar (H+)-ATPases--nature's most versatile proton pumps. Nat Rev Mol Cell Biol (2002) 5.19
Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A (2007) 4.05
Dissecting virus entry via endocytosis. J Gen Virol (2002) 3.74
Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol (2007) 3.57
Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol (2006) 3.33
Challenges and successes in developing new therapies for hepatitis C. Nature (2005) 3.22
Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology (2008) 3.09
The autophagy machinery is required to initiate hepatitis C virus replication. Proc Natl Acad Sci U S A (2009) 2.91
Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol (2006) 2.77
Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology (2008) 2.73
Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology (2008) 2.45
Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J Gen Virol (2009) 1.72
Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J Viral Hepat (2009) 1.62
Inhibition of peroxisome-proliferator-activated receptor (PPAR)alpha by MK886. Biochem J (2001) 1.42
The epidemiology of acute and chronic hepatitis C. Clin Liver Dis (1997) 1.36
Diverse and essential roles of mammalian vacuolar-type proton pump ATPase: toward the physiological understanding of inside acidic compartments. Biochim Biophys Acta (2004) 1.33
Infection of B lymphocytes by a human herpesvirus, Epstein-Barr virus, is blocked by calmodulin antagonists. Proc Natl Acad Sci U S A (1984) 1.31
Lysosomotropic agents. 1. Synthesis and cytotoxic action of lysosomotropic detergents. J Med Chem (1979) 1.26
Pterostilbene, a new agonist for the peroxisome proliferator-activated receptor alpha-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. J Agric Food Chem (2005) 1.22
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. J Med Chem (2007) 1.13
Tamoxifen inhibits acidification in cells independent of the estrogen receptor. Proc Natl Acad Sci U S A (1999) 1.12
Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity. J Cancer Res Clin Oncol (1992) 1.11
Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. J Pharm Sci (2007) 1.11
Peroxisome proliferator-activated receptor alpha antagonism inhibits hepatitis C virus replication. Chem Biol (2006) 1.04
A mechanism for tamoxifen-mediated inhibition of acidification. J Biol Chem (1999) 1.03
Selective inhibitors of hepatitis C virus replication. Antiviral Res (2006) 1.00
Anti-hepatitis C virus activity of tamoxifen reveals the functional association of estrogen receptor with viral RNA polymerase NS5B. J Biol Chem (2007) 0.99
Toremifene: an evaluation of its safety profile. Breast (2005) 0.99
Partitioning of local anesthetics into membranes: surface charge effects monitored by the phospholipid head-group. Biochim Biophys Acta (1988) 0.94
A review of rabeprazole in the treatment of acid-related diseases. Ther Clin Risk Manag (2007) 0.90
Inhibition of arenavirus multiplication in vitro by phenotiazines. Antiviral Res (1996) 0.83
Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level. Am J Respir Cell Mol Biol (2008) 0.83
3D cultured immortalized human hepatocytes useful to develop drugs for blood-borne HCV. Biochem Biophys Res Commun (2008) 0.82
Inhibition of intracellular hepatitis C virus replication by nelfinavir and synergistic effect with interferon-alpha. J Viral Hepat (2009) 0.79
Additive and synergistic effects of a novel antiestrogen, toremifene (Fc-1157a), and human interferons on estrogen responsive MCF-7 cells in vitro. Med Biol (1985) 0.77
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature (2007) 7.04
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A (2002) 5.81
Lambda interferon inhibits hepatitis B and C virus replication. J Virol (2005) 5.47
Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A (2002) 5.28
CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol (2003) 4.42
Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol (2006) 3.84
Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A (2005) 3.83
Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol (2007) 3.57
Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci U S A (2012) 3.50
Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A (2004) 3.16
Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest (2010) 3.10
Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics (2005) 2.99
Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol (2005) 2.94
The autophagy machinery is required to initiate hepatitis C virus replication. Proc Natl Acad Sci U S A (2009) 2.91
Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol (2006) 2.77
Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci U S A (2002) 2.71
Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. J Virol (2006) 2.68
Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol (2006) 2.65
Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci U S A (2003) 2.64
Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. Proc Natl Acad Sci U S A (2010) 2.46
Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. Cell Host Microbe (2009) 2.33
Double-stranded DNA and double-stranded RNA induce a common antiviral signaling pathway in human cells. Proc Natl Acad Sci U S A (2007) 2.33
Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. Cell Host Microbe (2012) 2.25
Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med (2005) 2.19
Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol (2005) 2.13
PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol (2007) 2.08
Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. J Virol (2002) 2.05
Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci U S A (2004) 1.96
Replication of a hepatitis C virus replicon clone in mouse cells. Virol J (2006) 1.90
Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. Hepatology (2014) 1.89
Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and -independent mechanisms. Proc Natl Acad Sci U S A (2006) 1.88
Oscillating CD8(+) T cell effector functions after antigen recognition in the liver. Immunity (2005) 1.83
Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A (2009) 1.76
The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol (2009) 1.71
Viruses and the autophagy machinery. Cell Cycle (2010) 1.68
Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice. J Virol (2002) 1.66
MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J Clin Invest (2004) 1.65
CD40 activation rescues antiviral CD8⁺ T cells from PD-1-mediated exhaustion. PLoS Pathog (2013) 1.65
Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J Virol (2010) 1.64
Immune tolerance split between hepatitis B virus precore and core proteins. J Virol (2005) 1.63
A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci U S A (2004) 1.61
Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol (2002) 1.61
Inhibition of hepatitis B virus replication by interferon requires proteasome activity. J Virol (2002) 1.58
Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections. J Virol (2002) 1.56
Gene expression during the priming phase of liver regeneration after partial hepatectomy in mice. Proc Natl Acad Sci U S A (2002) 1.51
Platelets prevent IFN-alpha/beta-induced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus. Proc Natl Acad Sci U S A (2008) 1.48
A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2008) 1.48
Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci U S A (2005) 1.47
Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma-derived cells. J Virol (2006) 1.47
Native hepatitis B virions and capsids visualized by electron cryomicroscopy. Mol Cell (2006) 1.44
Self-assembling peptide nanotubes with antiviral activity against hepatitis C virus. Chem Biol (2011) 1.41
Searching for interferon-induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes. J Virol (2003) 1.39
Transcriptional and posttranscriptional control of hepatitis B virus gene expression. Proc Natl Acad Sci U S A (2003) 1.35
Kupffer cells hasten resolution of liver immunopathology in mouse models of viral hepatitis. PLoS Pathog (2011) 1.34
Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. J Immunol (2002) 1.34
Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J Virol (2008) 1.33
Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc Natl Acad Sci U S A (2005) 1.30
Depletion of neutrophils blocks the recruitment of antigen-nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus-specific cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (2002) 1.29
Dynamics of hepatitis B virus clearance in chimpanzees. Proc Natl Acad Sci U S A (2005) 1.29
Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus. Proc Natl Acad Sci U S A (2008) 1.26
Hepatitis B small surface antigen particles are octahedral. Proc Natl Acad Sci U S A (2005) 1.25
Signal transduction pathways that inhibit hepatitis B virus replication. Proc Natl Acad Sci U S A (2004) 1.08
Hepatitis C virus (HCV) induces formation of stress granules whose proteins regulate HCV RNA replication and virus assembly and egress. J Virol (2012) 1.08
Detailed characterization of the peptide binding specificity of five common Patr class I MHC molecules. Immunogenetics (2006) 1.03
Autophagy proteins promote hepatitis C virus replication. Autophagy (2009) 1.02
Role of immunoproteasome catalytic subunits in the immune response to hepatitis B virus. J Virol (2006) 0.98
Characterization of the peptide-binding specificity of the chimpanzee class I alleles A 0301 and A 0401 using a combinatorial peptide library. Immunogenetics (2007) 0.97
Impact of the autophagy machinery on hepatitis C virus infection. Viruses (2011) 0.95
Pathogenic role of B cells in anti-CD40-induced necroinflammatory liver disease. Am J Pathol (2006) 0.94
Bortezomib inhibits hepatitis B virus replication in transgenic mice. Antimicrob Agents Chemother (2009) 0.89
Antiviral stilbene 1,2-diamines prevent initiation of hepatitis C virus RNA replication at the outset of infection. J Virol (2011) 0.86
Differential dynamics of the peripheral and intrahepatic cytotoxic T lymphocyte response to hepatitis B surface antigen. Virology (2005) 0.83
Sigma-1 receptor regulates early steps of viral RNA replication at the onset of hepatitis C virus infection. J Virol (2013) 0.78
Correction: CD40 Activation Rescues Antiviral CD8+ T Cells from PD-1-Mediated Exhaustion. PLoS Pathog (2016) 0.75
GB virus C and mortality from HIV infection. N Engl J Med (2002) 0.75
Pioneers of pathogenesis: past and present. Curr Opin Virol (2011) 0.75
Correction: CD40 Activation Rescues Antiviral CD8+ T Cells from PD-1-Mediated Exhaustion. PLoS Pathog (2017) 0.75